Transfer factor therapy in multiple sclerosis: A three-year prospective double blind clinical trial

Neurology

Volumn 36, Issue 10, 1986, Pages 1399-1402

  van Haver, H ^a   Lissoir, F ^b   Droissart, C ^b   Ketelaer, P ^b   van Hees, J ^a   Theys, P ^a   Vervliet, G ^a   Claeys, H ^c   Gautama, K ^c   Vermylen, C ^c   Carton, H ^a  

^a Department of NeurologyLeuven ^*  (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c Red Cross Blood Transfusion Center ^*  (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; PLACEBO; TRANSFER FACTOR;

CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG COMPARISON; DRUG DOSE; DRUG EFFICACY; DRUG THERAPY; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; METHODOLOGY; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; THERAPY;

ACTIVITIES OF DAILY LIVING; CLINICAL TRIALS; DOUBLE-BLIND METHOD; EVOKED POTENTIALS; FEMALE; HUMANS; INTERFERON TYPE II; KILLER CELLS, NATURAL; LEUKOCYTES; MALE; MULTIPLE SCLEROSIS; PROSPECTIVE STUDIES; TRANSFER FACTOR;

EID: 0022497910     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/wnl.36.10.1399     Document Type: Article

References (14)

1. Grob PS, Franke C, Reymond JF, Frei-Wettstein M. Therapeutic use of transfer factor. Eur J Clin Invest 1975;5:33–43.
2. Behan PO, Melville ID, Durward WF, McGeorg AP, Behan WMH. Transfer factor therapy in multiple sclerosis. Lancet 1976;1:988–9.
3. Fog T, Raun NE, Pedersen L, et al. Long-term transfer factor treatment for multiple sclerosis. Lancet 1978;1:851–3.
4. Collins RC, Espinoza LR, Plank CR, Ebers GC, Rosenberg RA, Rabiskie JB. A double-blind trial of transfer factor vs placebo in multiple sclerosis patients. Clin Exp Immunol 1978;33:1–11.
5. Lamoureux G, Cosgrove J, Duquette P, Lapierre Y, Jolicoeur R, Vanderland F. A clinical and immunological study of the effects of transfer factor on multiple sclerosis patients. Clin Exp Immunol 1981;43:557–64.
6. Basten A, Pollard JD, Stewart GJ, et al. Transfer factor in treatment of multiple sclerosis. Lancet 1980;2:931–4.
7. Schumacher GA, Beebe G, Kibler RF, et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann NY Acad Sci 1965;122:552–68.
8. Kurtzke JF. Neurologic impairment in multiple sclerosis and the disability status scale. Acta Neurol Scand 1970;46:493–512.
9. Laurence HS, Al-Ashari S. In: Bloom BR, Glade PM, eds. In vitro methods in cell-mediated immunity. New York Academic Press, 1971:531.
10. Ketelaer P. Melsbroek disability scoring test. Acta Neurol Scand 1981;64(suppl 87):74–5.
11. Van Haver H, Lissoir F, Theys P, et al. Transfer factor treatment in MS: a 3-year prospective double-blind study (1982–1985). In: Gonsette RE, Delmotte P, eds. Immunological and clinical aspects of multiple sclerosis. Lancaster, UK: MTP Press Limited, 1984:161–5.
12. Vervliet G, Claeys H, Van Haver H, et al. Interferon production and natural killer (NK) activity in leucocyte cultures from multiple sclerosis patients. J Neurol Sci 1983;60:137–50.
13. Claeys H, Van Damme J, De Ley M, Vermylen C, Billiau A. Activation of natural cytotoxicity of human peripheral mononuclear cells by interferon: a kinetic study and comparison of different interferon types. Br J Haematol 1982;50:85–94.
14. Van Rood JJA, Van Leeuwen A, Ploem JS. Simultaneous detection of two cell populations by two-colour fluorescence and application to the recognition of B-cell determinants. Nature 1982;262:795–7.